BioSpace News Archive

FDA

U.S. Food and Drug Administration Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) for Prevention of Hereditary Angioedema (HAE) Attacks in Pediatric Patients

CSL Behring, a global biotherapeutics leader, announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in patients 6 years of age and older.

September 28, 2020
·
8 min read
Pharm Country

EmblemHealth Study Finds New Yorkers Overall More Likely to Seek Flu Vaccine This Year Amid COVID-19

EmblemHealth, one of the nation’s largest nonprofit health insurers, released results of a new study that found that nearly half of New Yorkers will be more likely to get a flu vaccination this fall due to the ongoing coronavirus pandemic.

September 28, 2020
·
4 min read
Drug Development

PDS Biotechnology to Present Results from its Phase 1 Trial of PDS0101 and the Phase 2 Clinical Strategy in Patients with Advanced HPV-Associated Malignancies

PDS Biotechnology Corporation (“PDS Biotech” or the “Company”) (Nasdaq: PDSB), today announced that its Chief Medical Officer, Lauren V. Wood, M.D. will present key data from the company’s previously reported Phase 1 trial of PDS0101

September 28, 2020
·
2 min read
Biotech Beach

Heron Therapeutics Receives European Commission Authorization for ZYNRELEF™ (HTX-011) for the Treatment of Postoperative Pain

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the European Commission has granted a marketing authorization for ZYNRELEF (

September 28, 2020
·
5 min read